Anne Elizabeth Borgman

CIK: 0001886388

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)4 (33.3%)

Derivative conversions

Awards (A)5 (41.7%)

Compensation grants

Other (G, F, J, C, D, …)3 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

CRIS

CURIS INC

Director

NXTC

NextCure, Inc.

Director

STRO

SUTRO BIOPHARMA, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

CRIS
CURIS INC
Jul 7, 2026
Award(A)
Non Qualified Stock Option
Direct
6.8K shares at avg. $5.29-
NXTC
NextCure, Inc.
Jun 18, 2026
Award(A)
Stock Option (Right to Buy)
Direct
2.3K shares-
NXTC
NextCure, Inc.
Jun 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
18.7K shares-
CRIS
CURIS INC
May 20, 2025
Award(A)
Non Qualified Stock Option
Direct
14.4K shares at avg. $3.13-
STRO
SUTRO BIOPHARMA, INC.
May 1, 2025
Tax Payment(F)
Direct
24.7K shares at avg. $1.07$26K
STRO
SUTRO BIOPHARMA, INC.
May 1, 2025
Exercise(M)
Direct
15.9K shares-
STRO
SUTRO BIOPHARMA, INC.
May 1, 2025
Exercise(M)
Direct
53.1K shares-
STRO
SUTRO BIOPHARMA, INC.
Mar 1, 2025
Tax Payment(F)
Direct
4.6K shares at avg. $1.59$7K
STRO
SUTRO BIOPHARMA, INC.
Mar 1, 2025
Exercise(M)
Direct
11.3K shares-
STRO
SUTRO BIOPHARMA, INC.
Feb 28, 2025
Tax Payment(F)
Direct
15.4K shares at avg. $1.59$24K
STRO
SUTRO BIOPHARMA, INC.
Feb 28, 2025
Exercise(M)
Direct
37.5K shares-
CRIS
CURIS INC
Jan 28, 2025
Award(A)
Non Qualified Stock Option
Direct
1.6K shares at avg. $3.13-

		Type	Shares	Price		Ownership
Jul 7, 2026	CRIS CURIS INC	Award(A) Non Qualified Stock Option	6,800	$5.29	-	Direct
Jun 18, 2026	NXTC NextCure, Inc.	Award(A) Stock Option (Right to Buy)	2,340	-	-	Direct
Jun 20, 2025	NXTC NextCure, Inc.	Award(A) Stock Option (Right to Buy)	18,700	-	-	Direct
May 20, 2025	CRIS CURIS INC	Award(A) Non Qualified Stock Option	14,400	$3.13	-	Direct
May 1, 2025	STRO SUTRO BIOPHARMA, INC.	Tax Payment(F)	24,709	$1.07	$26,439	Direct
May 1, 2025	STRO SUTRO BIOPHARMA, INC.	Exercise(M)	15,938	-	-	Direct
May 1, 2025	STRO SUTRO BIOPHARMA, INC.	Exercise(M)	53,125	-	-	Direct
Mar 1, 2025	STRO SUTRO BIOPHARMA, INC.	Tax Payment(F)	4,621	$1.59	$7,347	Direct
Mar 1, 2025	STRO SUTRO BIOPHARMA, INC.	Exercise(M)	11,250	-	-	Direct
Feb 28, 2025	STRO SUTRO BIOPHARMA, INC.	Tax Payment(F)	15,405	$1.59	$24,494	Direct
Feb 28, 2025	STRO SUTRO BIOPHARMA, INC.	Exercise(M)	37,500	-	-	Direct
Jan 28, 2025	CRIS CURIS INC	Award(A) Non Qualified Stock Option	1,600	$3.13	-	Direct

1-12 of 12 transactions

About Borgman Anne Elizabeth

Borgman Anne Elizabeth (SEC CIK 0001886388) files insider reports with the SEC as Director of CURIS INC (CRIS), Director of NextCure, Inc. (NXTC) and CHIEF MEDICAL OFFICER of SUTRO BIOPHARMA, INC. (STRO).

Signal8 holds 7 ownership filings by Borgman Anne Elizabeth, all Form 4s, filed between Jan 30, 2025 and Jul 9, 2026. Those filings report 12 transactions, from Jan 28, 2025 to Jul 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Borgman Anne Elizabeth's filings is in LEXINGTON, MA.

Recent filings by Borgman Anne Elizabeth

Jul 7, 2026: Grant or award of CRIS derivative securities (Form 4, code A).
Jun 18, 2026: Grant or award of NXTC derivative securities (Form 4, code A).
Jun 20, 2025: Grant or award of NXTC derivative securities (Form 4, code A).
May 20, 2025: Grant or award of CRIS derivative securities (Form 4, code A).
May 1, 2025: Tax withholding of STRO shares (Form 4, code F).

Other insiders filing for CURIS INC (CRIS)

How to read Form 4 transaction codes